What’s the preferred breast cancer screening modality? When should patients begin screening mammograms? Are guidelines being considered? We compiled the data.
[[{"type":"media","view_mode":"media_crop","fid":"25331","attributes":{"alt":"","class":"media-image","id":"media_crop_2606298220343","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2310","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"line-height: 1.538em;","title":" ","typeof":"foaf:Image"}}]]
The breast cancer screening debate is ongoing, but the results of our 2014 Breast Cancer Screening Survey are in. We polled readers from Diagnostic Imaging and obgyn.net to see what clinicians are using and recommending for breast cancer screening.
As expected, mammography is the most preferred method of screening. Part of the controversy about breast cancer screening is the recommended age of biennial screening for average-risked women, which the United States Preventive Services Task Force (USPSTF) recommends beginning at age 50, however, almost half of our respondents recommend beginning biennial screening at age 40. The USPSTF is in the process of updating their recommendations, which reconsiders the recommended age to begin screening and the effectiveness of screening based on modality.
Almost all respondents (91 percent) recommend supplemental screening for women at high-risk of breast cancer. Ultrasound was the supplemental modality of choice for 37 percent of the respondents, with MRI coming close behind at 35 percent.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.